Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.
Citius Pharmaceuticals reports developments across its critical care and targeted oncology business, including activity at majority-owned subsidiary Citius Oncology. The company’s recurring updates center on LYMPHIR (denileukin diftitox-cxdl), an engineered IL-2 diphtheria toxin fusion protein approved for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.
Company news also covers LYMPHIR commercialization, U.S. launch progress, international access through Named Patient Programs, and investigator-initiated oncology studies involving gynecologic cancers and diffuse large B-cell lymphoma. Capital updates include registered direct offerings, warrant issuances, non-dilutive funding and other financing actions that support product commercialization and development programs.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has announced a registered direct offering to sell 50,830,566 shares of common stock at $1.505 per share, along with warrants for an additional 25,415,283 shares at an exercise price of $1.70. The offering is expected to close around February 19, 2021, with gross proceeds of approximately $76.5 million. Funds will be used for general corporate purposes, including clinical development of product candidates. H.C. Wainwright & Co. is the exclusive placement agent for this offering.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) released a shareholder letter detailing its recent achievements and plans for 2021. Key updates include expected interim analysis from the Mino-Lok® pivotal trial and filing of the Halo-Lido IND and Phase 2b protocol in Q2. The company is also progressing with Mino-Wrap™ and its NoveCite i-MSCs program. A recent private placement raised $20 million, and warrant exercises generated an additional $4.5 million. These developments reflect Citius's commitment to advancing its clinical programs, aiming for significant milestones this year.
Citius Pharmaceuticals (Nasdaq: CTXR) will present at the Virtual Investor Conferences Small and Microcap Showcase on February 4, 2021, at 1:00 p.m. ET. Chairman Leonard Mazur will provide updates on the lead candidate MinoLok, currently in Phase 3 trials, as well as three other active programs. The event is interactive, allowing real-time questions from investors. An archived version will be available post-event. Pre-registration is recommended for participation.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has completed a private placement, raising approximately $20.0 million by issuing 15,455,960 shares of common stock priced at $1.294 per share, along with warrants for an additional 7,727,980 shares. The associated warrants have an exercise price of $1.231 and are valid for five and a half years. Proceeds will support general corporate purposes, including pre-clinical and clinical development. The company has obligations to file a registration statement with the SEC to facilitate resale of the shares.
Citius Pharmaceuticals (CTXR) announces a private placement to raise approximately $20.0 million by issuing 15,455,960 shares of common stock and warrants for 7,727,980 shares at $1.294 per share. The placement is set to close around January 27, 2021, subject to closing conditions. H.C. Wainwright & Co. is the exclusive placement agent. Funds will support clinical development and working capital. Citius must file a registration statement for resale within five days, aiming for effectiveness within 75 days.
Citius Pharmaceuticals, a specialty pharmaceutical company (Nasdaq: CTXR), announced presentations at two virtual investor conferences in January 2021. The H.C. Wainwright BioConnect Conference will feature CEO Myron Holubiak from January 11-14, with a presentation available on-demand starting January 11. The MoneyShow Accredited Investors Virtual Expo will feature Chairman Leonard Mazur on January 26. Key updates will include progress on i-MSC therapy for ARDS and Mino-Lok trials for CLABSIs. Citius is committed to advancing its product candidates in critical care.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has announced a series of webinars to discuss updates on the Phase 3 trial of Mino-Lok, an antibiotic lock solution designed for treating Central Line Associated Blood Stream Infections (CLABSIs). The trial is over halfway complete, with insights shared by experts from leading medical institutions. Key topics included the challenges of conducting the trial during COVID-19 and the benefits of Mino-Lok. CEO Myron Holubiak expressed optimism about meeting the unmet need for effective alternatives to central line replacements.
Citius Pharmaceuticals (CTXR) announced receiving guidance from the FDA regarding its Mino-Wrap, aimed at reducing infections in post-mastectomy patients. The FDA's feedback included suggestions for bio absorption studies and a large animal pharmacology study to support Mino-Wrap's development. Additionally, a 28-day toxicology study was deemed appropriate. This innovation, designed to enhance protection against infections during breast reconstruction surgeries, could address a significant issue, as infection rates for tissue expanders range from 2.5% to 24%. Citius emphasizes the importance of this solution amid current inadequate preventive measures.
Citius Pharmaceuticals (Nasdaq: CTXR) announced promising interim data from a proof-of-concept study on its proprietary induced mesenchymal stem cell (i-MSC) therapy for acute inflammatory respiratory conditions, such as COVID-19 related ARDS. The study showed significant improvements in oxygenation, reduced lung injury, and systemic shock in treated subjects compared to controls. Citius has partnered with Novellus Therapeutics for the development of i-MSCs and established a subsidiary, NoveCite, which has filed a Pre-IND with the FDA, indicating strong progress in their therapeutic approach.
Citius Pharmaceuticals (Nasdaq: CTXR) announced its participation in the Benzinga Global Small Cap Conference on December 8-9, 2020. Citius Chairman Leonard Mazur will present on December 8 at 11:30 am ET and conduct one-on-one meetings with investors. The company is advancing four proprietary product candidates, including Mino-Lok®, which is in Phase 3 trials, and Halo-Lido, expected to enter Phase 2b trials in early 2021. Recent developments include a positive interim analysis for Mino-Lok and an exclusive agreement with Novellus Therapeutics for a therapy related to COVID-19.